Abstract
In a phase II study, researchers found that the PARP inhibitor olaparib led to stable disease or tumor regressions in patients with advanced breast, ovarian, pancreatic, and prostate cancers who had germline mutations in BRCA1 or BRCA2.
©2014 American Association for Cancer Research.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Female
-
Humans
-
Male
-
Neoplasm Staging
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / pathology*
-
Phthalazines / pharmacology
-
Phthalazines / therapeutic use*
-
Piperazines / pharmacology
-
Piperazines / therapeutic use*
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Poly(ADP-ribose) Polymerases / genetics
Substances
-
Antineoplastic Agents
-
Phthalazines
-
Piperazines
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Poly(ADP-ribose) Polymerases
-
olaparib